Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer

BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefore significant interest in developing novel therape...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Li, Ling, Hobson, Lisa, Perry, Laura, Clark, Bethany, Heavey, Susan, Haider, Aiman, Sridhar, Ashwin, Shaw, Greg, Kelly, John, Freeman, Alex, Wilson, Ian, Whitaker, Hayley, Nurmemmedov, Elmar, Oltean, Sebastian, Porazinski, Sean, Ladomery, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7493922/
https://ncbi.nlm.nih.gov/pubmed/32581342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0951-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares